This study is testing if the drug camizestrant helps people with early-stage ER+/HER2- breast cancer, which is a type of cancer that grows in response to hormones like estrogen (ER stands for estrogen receptor positive, and HER2- means the cancer does not have too much of a protein called HER2). After surgery and possibly other treatments like chemotherapy, the study checks if camizestrant is better than usual hormone treatments. People in the study will take their assigned treatment for 7 years, and researchers will check their health for up to 10 years. The main thing they are looking at is how long people stay free from invasive cancer, meaning the cancer hasn't come back or spread.

Key Points:

• The study lasts up to 10 years, with 7 years of treatment.
• Participants must have had certain treatments already, like surgery.
• People can join if they are 18 or older and meet the study's health requirements.